KR960700723A - Aids-관련 신경 장애를 치료하기 위한 카르바마제핀 및 옥스카르바제핀과 같은 항간질제의 사용(use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders) - Google Patents

Aids-관련 신경 장애를 치료하기 위한 카르바마제핀 및 옥스카르바제핀과 같은 항간질제의 사용(use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders) Download PDF

Info

Publication number
KR960700723A
KR960700723A KR1019950703733A KR19950703733A KR960700723A KR 960700723 A KR960700723 A KR 960700723A KR 1019950703733 A KR1019950703733 A KR 1019950703733A KR 19950703733 A KR19950703733 A KR 19950703733A KR 960700723 A KR960700723 A KR 960700723A
Authority
KR
South Korea
Prior art keywords
oxcarbazepine
carbamazepine
pharmaceutically acceptable
treatment
antiepileptics
Prior art date
Application number
KR1019950703733A
Other languages
English (en)
Inventor
부소 앤느
도블 아담
루벨 에릭
Original Assignee
모르뱅 미쉘
로오느-푸우랜크 로레르 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르뱅 미쉘, 로오느-푸우랜크 로레르 소시에테 아노님 filed Critical 모르뱅 미쉘
Publication of KR960700723A publication Critical patent/KR960700723A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

AIDS-관련 신경 장애를 치료하기 위한 카르바마제핀 및 옥스카르바제 또는 그의 제약학적으로 허용가능한 염으로부터 선택된 항간질제의 사용이 공객된다

Description

AIDS-관련 신경 장애를 치료하기 위한 카르바마제핀 및 옥스카르바제핀과 같은 항간질제의 사용(USE OF ANTIEPILEPTICS SUCH AS CARBAMAZEPINE AND OXCARBAZEPINE FOR TREATING AIDS-RELATED NEURAL DISORDERS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 신경-AIDS의 치료를 위한 약제 생성물의 제조에 있어서 카르바마제핀 및 옥스카르바제핀 또는 상기 화합물의 제약학적으로 허용가능한 염으로부터 선택된 진경제의 사용.
  2. 제1항에 있어서, 치매, 인식장애, 신경병, 근병, 눈 장애 및 HIV-1 비루스와 관련된 모든 신경적 증후군을 포함하는 질병의 치료를 위한 약제 생성물의 제조를 위한 사용.
  3. 제1항에 있어서, 진경제 25-200㎎로 구성되는 약제 생성물을 얻기 위한 사용.
  4. 신경-AIDS의 치료에 유용한 약제 생성물을 제조하는 방법으로서, 카르바마제핀 및 옥스카르바제핀 또는 상기 화합물의 제약학적으로 허용가능한 염으로부터 선택된 진경제를 하나 이상의 사용가능하고 제약학적으로 허용가능한 희석제 및/또는 보조제와 혼합하는 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950703733A 1993-03-05 1994-02-25 Aids-관련 신경 장애를 치료하기 위한 카르바마제핀 및 옥스카르바제핀과 같은 항간질제의 사용(use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders) KR960700723A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR93/02568 1993-03-05
FR9302568A FR2702148B1 (fr) 1993-03-05 1993-03-05 Application d'anticonvulsivants dans le traitement du neuro-sida.
PCT/FR1994/000209 WO1994020110A1 (fr) 1993-03-05 1994-02-25 APPLICATION D'ANTICONVULSIVANTS COMME LA CARBAMAZEPINE ET l'OXCARBAZEPINE, DANS LE TRAITEMENT DU NEURO-SIDA

Publications (1)

Publication Number Publication Date
KR960700723A true KR960700723A (ko) 1996-02-24

Family

ID=9444690

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1019950703733A KR960700723A (ko) 1993-03-05 1994-02-25 Aids-관련 신경 장애를 치료하기 위한 카르바마제핀 및 옥스카르바제핀과 같은 항간질제의 사용(use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders)
KR1019950703732A KR100318168B1 (ko) 1993-03-05 1994-02-25 리루졸을포함하는뉴로-aids치료를위한제약학적조성물
KR1019950703734A KR960700721A (ko) 1993-03-05 1994-02-25 Aids-관련 신경 장애를 치료하기 위한 라모트리진의 사용(use of lamotrigine for treating aids-related neural disorders)

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1019950703732A KR100318168B1 (ko) 1993-03-05 1994-02-25 리루졸을포함하는뉴로-aids치료를위한제약학적조성물
KR1019950703734A KR960700721A (ko) 1993-03-05 1994-02-25 Aids-관련 신경 장애를 치료하기 위한 라모트리진의 사용(use of lamotrigine for treating aids-related neural disorders)

Country Status (23)

Country Link
US (2) US5629312A (ko)
EP (3) EP0687176B1 (ko)
JP (3) JPH08507509A (ko)
KR (3) KR960700723A (ko)
AT (2) ATE201597T1 (ko)
AU (3) AU6143894A (ko)
CA (3) CA2154573A1 (ko)
CZ (3) CZ226095A3 (ko)
DE (2) DE69401577T2 (ko)
DK (2) DK0687176T3 (ko)
ES (2) ES2096455T3 (ko)
FR (1) FR2702148B1 (ko)
GR (2) GR3022356T3 (ko)
HU (3) HU9502584D0 (ko)
IL (3) IL108846A0 (ko)
NO (3) NO307687B1 (ko)
PL (3) PL310476A1 (ko)
PT (1) PT687176E (ko)
RU (1) RU2157205C2 (ko)
SK (3) SK107595A3 (ko)
UA (1) UA41355C2 (ko)
WO (3) WO1994020110A1 (ko)
ZA (2) ZA941530B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5922746A (en) * 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
GB9721497D0 (en) 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
AU4424500A (en) * 1999-04-29 2000-11-17 Centre National De La Recherche Scientifique (C.N.R.S.) A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6207179B1 (en) * 2000-05-18 2001-03-27 Phoenix Scientific, Inc. Parasiticidal formulation for animals and a method of making this formulation
CA2471666C (en) 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
PT2982372T (pt) * 2005-04-05 2020-10-09 Univ Yale Agentes moduladores do glutamato no tratamento de distúrbios mentais
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
SG11201703896QA (en) * 2014-11-21 2017-06-29 Biohaven Pharm Holding Co Ltd Sublingual formulation of riluzole
EP4298191A1 (en) * 2021-02-24 2024-01-03 Valvoline Licensing and Intellectual Property, LLC Foaming evaporator coil cleaner

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
JPH07308499A (ja) * 1994-05-20 1995-11-28 Brother Ind Ltd 衣類乾燥機

Also Published As

Publication number Publication date
PL310475A1 (en) 1995-12-11
JP3578174B2 (ja) 2004-10-20
HU9502585D0 (en) 1995-11-28
FR2702148A1 (fr) 1994-09-09
AU6143794A (en) 1994-09-26
IL108845A0 (en) 1994-06-24
KR100318168B1 (ko) 2002-06-20
NO953371L (no) 1995-08-28
DK0687176T3 (da) 2001-07-30
KR960700716A (ko) 1996-02-24
CA2154571A1 (fr) 1994-09-15
NO953371D0 (no) 1995-08-28
CZ225995A3 (en) 1995-12-13
GR3035957T3 (en) 2001-08-31
DE69401577T2 (de) 1997-05-15
EP0687177A1 (fr) 1995-12-20
US5629312A (en) 1997-05-13
EP0687177B1 (fr) 1997-01-22
CZ226095A3 (en) 1995-12-13
WO1994020103A1 (fr) 1994-09-15
WO1994020110A1 (fr) 1994-09-15
PT687176E (pt) 2001-09-28
RU2157205C2 (ru) 2000-10-10
ATE147981T1 (de) 1997-02-15
EP0687176A1 (fr) 1995-12-20
UA41355C2 (uk) 2001-09-17
ZA941530B (en) 1994-10-06
HU217132B (hu) 1999-11-29
HU9502584D0 (en) 1995-11-28
PL310474A1 (en) 1995-12-11
EP0687179A1 (fr) 1995-12-20
IL108846A0 (en) 1994-06-24
NO953372L (no) 1995-08-28
AU675118B2 (en) 1997-01-23
HUT73434A (en) 1996-07-29
KR960700721A (ko) 1996-02-24
CZ226195A3 (en) 1995-12-13
DE69427344T2 (de) 2002-04-25
HU9502583D0 (en) 1995-11-28
CA2154572A1 (fr) 1994-09-15
DE69427344D1 (de) 2001-07-05
CA2154573A1 (fr) 1994-09-15
CA2154572C (fr) 2006-06-06
WO1994020108A1 (fr) 1994-09-15
DK0687177T3 (da) 1997-02-10
EP0687176B1 (fr) 2001-05-30
SK107595A3 (en) 1996-06-05
IL108844A (en) 1998-01-04
DE69401577D1 (de) 1997-03-06
ZA941525B (en) 1994-11-09
ATE201597T1 (de) 2001-06-15
FR2702148B1 (fr) 1995-04-07
JPH08507507A (ja) 1996-08-13
NO307687B1 (no) 2000-05-15
AU675119B2 (en) 1997-01-23
SK279659B6 (sk) 1999-02-11
ES2096455T3 (es) 1997-03-01
NO953370D0 (no) 1995-08-28
GR3022356T3 (en) 1997-04-30
SK107695A3 (en) 1996-06-05
SK107495A3 (en) 1996-06-05
CZ285339B6 (cs) 1999-07-14
CZ284423B6 (cs) 1998-11-11
ES2157252T3 (es) 2001-08-16
IL108844A0 (en) 1994-06-24
PL310476A1 (en) 1995-12-11
AU6143994A (en) 1994-09-26
US5624945A (en) 1997-04-29
JPH08507508A (ja) 1996-08-13
JPH08507509A (ja) 1996-08-13
AU6143894A (en) 1994-09-26
NO953370L (no) 1995-08-28
HUT73433A (en) 1996-07-29
NO953372D0 (no) 1995-08-28

Similar Documents

Publication Publication Date Title
KR960700723A (ko) Aids-관련 신경 장애를 치료하기 위한 카르바마제핀 및 옥스카르바제핀과 같은 항간질제의 사용(use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders)
DE59310085D1 (de) Indolocarbazol-imide und deren verwendung
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
ATE212223T1 (de) Verwendung von sertraline zur herstellung eines arzneimittels zur behandlung von obsessiv- kompulsiven erkrankungen
KR960700054A (ko) 파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
NO306677B1 (no) Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament
FI954130A (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
NO302523B1 (no) Heterosykliske forbindelser, farmasöytiske preparater som omfatter dem, og anvendelse av forbindelsene for fremstilling av medikamenter
RU93051352A (ru) Замещенные производные циклогексана, способ их получения и применение соединений для лечения заболеваний
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
ATE123024T1 (de) 4-aminopyridinderivate.
KR920002151A (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
DE69506686T2 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
FI885560A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
ATE159427T1 (de) Anwendung des n-n-butyl-derivates von desoxynojirimycin zur herstellung eines arzneimittels zur inhibierung von hiv-virus
KR980000445A (ko) 인식 증강 방법
NO175745C (no) Analogifremgangsmåte for fremstilling av dibenzo(1,5)-dioksocin-5-oner
HUP9701150A2 (hu) Azaxantonszármazékok alkalmazása látászavarok megelőzésére és kezelésére szolgáló gyógyszerkészítmények előállítására
DE3764559D1 (de) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid, dessen herstellung und verwendung.
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE169922T1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
NO952559D0 (no) N-acyl-pyrrolidiner og medikamenter for behandling eller prevensjon av cholecystokinin- og gastrin-relaterte mangler
RU95106652A (ru) Оптически активные производные карбоксамида, аналгезирующее средство
DE69404322T2 (de) 3-aryl-4-alkyl und 4,5-dialkyl-4h-1,2,4-triazole, verwendbar gegen gedächtnis-störungen

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid